Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX versus FOLFOX in non-metastatic colon cancer
IRCT20210913052454N1Phase 2Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoints: Local recurrence, Distant metastasis and 1 more. Started Sep 2021; status: completed.
02
Drugs
capecitabineoxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on IRCT20210913052454N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210913052454N1.